FREEDOM Extension Trial for Denosumab
Yes, patients can be enrolled in denosumab extension trials, with the FREEDOM Extension demonstrating that continuous denosumab 60 mg subcutaneously every 6 months for up to 10 years maintains efficacy with acceptable safety, though strict adherence to the 6-month dosing interval is critical to prevent rebound vertebral fractures.
Extension Trial Evidence
The FREEDOM Extension trial enrolled 4,550 postmenopausal women with osteoporosis who completed the initial 3-year FREEDOM trial 1. This created two groups:
- Long-term group: Received denosumab for 3 years in FREEDOM, then continued for 7 more years (total 10 years)
- Crossover group: Received placebo in FREEDOM, then switched to denosumab for up to 7 years
Dosing Protocol
The standard dosing remains 60 mg subcutaneously every 6 months 2. This dose was maintained throughout the entire 10-year extension period 3. The FDA label explicitly states: "If a dose of Prolia is missed, administer the injection as soon as the patient is available. Thereafter, schedule injections every 6 months from the date of the last injection" 2.
Efficacy Outcomes Through 10 Years
Bone Mineral Density Gains
In the long-term group receiving 10 years of continuous denosumab 3:
- Lumbar spine: +21.7% from baseline
- Total hip: +9.2%
- Femoral neck: +9.0%
Critically, BMD continued to increase throughout the entire 10-year period without plateau 3. A recent 2026 real-world study confirmed these findings, showing +16.3% lumbar spine and +12.9% total hip gains over 10 years 4.
Fracture Rates
Yearly incidence of new vertebral fractures remained consistently low (0.90%-1.86%) and nonvertebral fractures (0.84%-2.55%) throughout the extension 3. These rates were substantially lower than projected for a virtual placebo cohort.
Prior Bisphosphonate Exposure
Prior bisphosphonate use does not impair long-term denosumab response 4. While early biochemical markers may differ, decade-long BMD trajectories are equivalent regardless of prior bisphosphonate exposure.
Monitoring Requirements
Standard Monitoring
All patients require 2:
- Calcium supplementation: 1,000 mg daily
- Vitamin D supplementation: At least 400 IU daily (higher doses often needed)
High-Risk Populations Requiring Intensive Monitoring
Patients with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m²) face markedly elevated hypocalcemia risk 2:
- Monitor serum calcium weekly for the first month after each dose
- Then monthly thereafter
- Assess baseline: intact PTH, serum calcium, 25(OH) vitamin D, 1,25(OH)₂ vitamin D
- Consider bone turnover markers or bone biopsy to evaluate underlying bone disease
- Requires supervision by a provider experienced in CKD-mineral bone disorder management
Patients predisposed to hypocalcemia (hypoparathyroidism, thyroid/parathyroid surgery, malabsorption, concurrent calcium-lowering drugs) 2:
- Check serum calcium, phosphorus, and magnesium 10-14 days after each injection
Dental Monitoring
Mandatory oral examination before initiating therapy 1. Avoid invasive dental procedures (extractions, implants) during treatment. The 10-year extension data showed 13 total cases of osteonecrosis of the jaw (ONJ) in the long-term group and 6 in the crossover group 3.
Safety Profile Over 10 Years
The exposure-adjusted incidence of adverse events decreased over time, from 165.3 to 95.9 per 100 participant-years 3. Serious adverse event rates remained stable (11.5-14.4 per 100 participant-years) 3.
Rare but Serious Events
- Atypical femoral fractures: 1 case in each group during the extension 3
- ONJ: 7 cases (long-term) and 6 cases (crossover) through 10 years 3
These rates remained acceptably low and did not increase with prolonged exposure 5.
Critical Dosing Adherence Warning
Strict adherence to the 6-month dosing interval is non-negotiable. Dosing intervals >210 days (7 months) occurred in 14.8% of doses in a 2026 Australian study, affecting 20% of residents 6. Delayed or missed doses trigger rapid bone resorption and dramatically increase vertebral fracture risk.
If denosumab must be discontinued, immediate transition to a bisphosphonate is mandatory to prevent rebound vertebral fractures 6. In the Australian study, 98.2% of patients who stopped denosumab did NOT receive appropriate bisphosphonate replacement—a dangerous practice gap 6.
Contraindications to Extension Enrollment
Absolute contraindications 2:
- Pre-existing hypocalcemia (must correct before any dose)
- Pregnancy (requires pregnancy testing in women of reproductive potential)
- Prior systemic hypersensitivity to denosumab (anaphylaxis, facial swelling, urticaria)
Context: Adjuvant Use in Breast Cancer
While the FREEDOM Extension supports long-term osteoporosis treatment, ASCO guidelines do NOT recommend denosumab to reduce breast cancer recurrence 7. The D-CARE trial using higher-dose denosumab (120 mg monthly) showed no improvement in bone metastasis-free survival and unacceptably high ONJ rates (5% vs <1% placebo) 7. The lower-dose ABCSG-18 trial showed promise but conflicting results led to no recommendation for anticancer benefit 7.